Approval · Notice of Compliance 38157 · 2026
APO-DIVALPROEX: Notice of Compliance 38157
Issued August 21, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38157
- Date
- August 21, 2026
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Update to labelling (to match Licensor).
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-DIVALPROEX | Not yet assigned | — |
Medicinal ingredients
- VALPROIC ACID 125 MG per TAB
- VALPROIC ACID 250 MG per TAB
- VALPROIC ACID 500 MG per TAB